泰素联合草酸铂与泰素联合顺铂治疗中晚期非小细胞肺癌的疗效观察

目的：探讨草酸铂与顺铂联合泰素治疗中晚期非小细胞肺癌的疗效及不良反应。方法：选出符合入选标准的40例患者,随机分成2组,草酸铂组21例,泰素175 mg/m^2静脉滴注第1天,草酸铂130 mg/m^2静脉滴注第1天;顺铂组19例,泰素175 mg/m^2静脉滴注第1天,顺铂80 mg/m^2静脉滴注第1天、第2天、第3天。两组病人使用泰素前12 h及6 h各口服地塞米松7.5 mg,使用泰素前30 min给予苯海拉明25 mg肌注,西米替丁0.4 g静注。并且使用泰素时滴注时间均超过3 h。草酸铂组使用糖配用,滴注时间均超过3 h。2组化疗前常规止呕等治疗。21天为1个周期,2个周期后评价疗效。结果：全部患者均完成2个周期的治疗。并且无1例出现对泰素的过敏反应。2组患者疗效经检验无统计学意义（P〉0.05）。2组患者不良反应比较：恶心呕吐及颜面水肿有统计学意义（P〈0.05）,白细胞下降、感觉神经异常及血小板下降均无统计学意义（P〉0.05）。结论：泰素联合草酸铂与泰素联合顺铂治疗中晚期非小细胞肺癌的近期疗效相当,但联合草酸铂不良反应相对较小,对顺铂反应强烈者可考虑使用草酸铂。

The compaison of taxol combined oxaliplatin and cisplatin for the advanced stage nonsmall-cell lung cancer treatment

Objective： To probe the curative and adverse effects of the taxol combined oxaliplatin or cisplatin for the advanced stage nonsmall-cell lung cancer （NSCLC）. Methods： 40 cases suffered from NSCLC were divided into two groups randomly, 21 patients were treated with taxol combined oxaliplatin, taxol IV dropped 175 mg/m^2 and oxaliplatinat IV dropped 130 mg/m^2 at first day. 19 patients were treated with taxol combined cisplatin, taxol IV dropped 175 mg/m^2 and cisplatin IV dropped 80 mg/m^2 at first day. All the patients took orally dexamethasone before recived the taxol at 12 h and 6 h with the dose of 7.5 rag, phenergan 25 mg were intramusculared before 30 min and cimetidine 0.4 g were intravenous injected too. All the instillation time were longer than 3 hours. Both groups of the groups patients were performed anti-vomitting treatment. A cycle time including 21 days and the curative effects were evaluated after 2 cycles. Results： All the patients were received 2 cycles treatment and no anaphylaxis oecured. In the group treated with oxaliplatin, 5 cases were CR ＋ PR and the effective rate was 23.8% （5/21）. In the group treated with cisplatin, 6 eases were CR ＋ PR and the effective rate was 31.57% （6/19）. There was no statistically significant between two groups（ P 〉 0.05 ）. There were statistically significance between the comparsion of vomitting and the facial dropsy and other adverers effects （ P 〈 0.05 ） , while there were no statistically significance among the eomparsion of leucocyte decrease, nervus sensorialis abnormality and platelet decrease（ P 〉0.05 ）. Condusions ： The shortly curative effects of the taxol combined oxaliplatin or cisplatin for the advanced stage SCLC were equal. The adverse reactions were less treated with oxaliplatin and it was selected for the intensive rection treated with eisplatin.